Directorate Change

Oxford Biomedica PLC
04 March 2005


FOR IMMEDIATE RELEASE          4 MARCH 2005

                  OXFORD BIOMEDICA ANNOUNCES BOARD APPOINTMENT



Oxford, UK - 4 March 2005: Oxford BioMedica (LSE:OXB.L), the leading gene
therapy company, today announces that Nick Woolf has been promoted to the Board
as an executive director. He will maintain his title of Senior Vice President
for Corporate Strategy. His primary responsibilities include corporate finance,
M&A evaluation and corporate communications as well as an important role,
jointly with Peter Nolan, in business development and deal negotiation.



Prior to joining Oxford BioMedica in 2002, Nick spent eight years as a top-rated
biotechnology and pharmaceutical analyst. Nick has been involved in all aspects
of company financing, ranging from IPOs to major corporate deals. He served as
Director and Head of European Biotechnology Research at ABN AMRO, and was
previously with Robertson Stephens International, Nomura and SBC Warburg. Nick
holds an MA from Oxford University in Chemistry.



Commenting on the Board appointment, Professor Alan Kingsman, Chief Executive of
Oxford BioMedica, said: 'Nick has contributed at a very high level to all
corporate activities and has been instrumental in raising the Company's profile
in the industry and the investment community. We are delighted to welcome him to
the Board.'



-Ends-


For further information, please contact:
Oxford BioMedica plc:

Professor Alan Kingsman, Chief Executive                 Tel: [phone]
City/Financial Enquiries:

Lisa Baderoon/ Mark Court/ Mary-Jane Johnson Buchanan    Tel: [phone]
Communications
Scientific/Trade Press Enquiries:

Sue Charles/ Katja Stout/ Ashley Lilly                   Tel: [phone]

Northbank Communications



Notes to editors



1. Oxford BioMedica

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the
development of novel gene-based therapeutics with a focus on the areas of
oncology and neurotherapy. The Company was established in 1995 as a spin out
from Oxford University, and is listed on the London Stock Exchange.



Oxford BioMedica has core expertise in gene delivery, as well as in-house
clinical, regulatory and manufacturing know-how. In oncology, the pipeline
includes an immunotherapy and a gene therapy in multiple Phase II trials, and a
preclinical targeted antibody therapy in collaboration with Wyeth. In
neurotherapy, the Company's lead product is a gene therapy for Parkinson's
disease, which is expected to enter clinical development in 2005, and four
further preclinical candidates. The Company is underpinned by over 80 patent
families, which represent one of the broadest patent estates in the field.



The Company has a staff of approximately 65 split between its main facilities in
Oxford and its wholly owned subsidiary, BioMedica Inc, in San Diego, California.
Oxford BioMedica has corporate collaborations with Wyeth, Intervet, Amersham,
Viragen, MolMed and Kiadis; and has licensed technology to a number of companies
including Merck & Co and Biogen Idec.



Further information is available at www.oxfordbiomedica.co.uk.



                      This information is provided by RNS
            The company news service from the London Stock Exchange      BOAUUUGPWUPAUBC